<DOC>
	<DOCNO>NCT00805194</DOCNO>
	<brief_summary>The present trial perform evaluate whether BIBF 1120 combination standard therapy docetaxel patient stage IIIB/IV recurrent NSCLC effective compare placebo combination standard therapy docetaxel . A secondary aim obtain safety information well information quality life patient treat BIBF 1120 combination standard therapy docetaxel . In addition , blood collect pharmacokinetic analysis .</brief_summary>
	<brief_title>LUME-Lung 1 : BIBF 1120 Plus Docetaxel Compared Placebo Plus Docetaxel 2nd Line Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : male female patient age 18 year old ; histologically cytologically confirm , locally advanced and/or metastatic NSCLC stage IIIB IV recurrent NSCLC ; relapse failure one first line prior chemotherapy ; least one target tumour lesion irradiate within past three month accurately measure ; life expectancy least three month ; ECOG score 0 1 ; patient give write informed consent Exclusion criterion : one prior chemotherapy regimen advance and/or metastatic recurrent NSCLC ; one chemotherapy treatment regimen ( either neoadjuvant adjuvant neoadjuvant plus adjuvant ) prior first line chemotherapy ; previous therapy VEGFR inhibitor ( bevacizumab ) docetaxel treatment NSCLC ; persistence clinically relevant therapy relate toxicity previous chemotherapy and/or radiotherapy ; treatment investigational drug anticancer therapy treatment another clinical trial within past four week start therapy concomitantly trial ; radiotherapy ( except extremity brain ) within past three month prior baseline image ; active brain metastasis leptomeningeal disease ; radiographic evidence cavitary necrotic tumour ; centrally locate tumour radiographic evidence ( CT MRI ) local invasion major blood vessel ; history clinically significant haemoptysis within past 3 month ; therapeutic anticoagulation ( except low dose heparin ) antiplatelet therapy ; history major thrombotic clinically relevant major bleed event past 6 month ; know inherited predisposition bleed thrombosis ; significant cardiovascular disease ; inadequate safety laboratory parameter ; significant weight loss ( &gt; 10 % ) within past 6 week ; current peripheral neuropathy great CTCAE grade 2 except due trauma ; preexist ascites and/or clinically significant pleural effusion ; major injury and/or surgery within past ten day prior randomisation incomplete wound heal ; serious infection require systemic antibiotic therapy ; decompensated diabetes mellitus contraindication high dose corticosteroid therapy ; gastrointestinal disorder abnormality would interfere absorption study drug ; active chronic hepatitis C and/or B infection ; serious illness concomitant nononcological disease laboratory abnormality may increase risk associate study participation study drug administration ; patient sexually active unwilling use medically acceptable method contraception trial least twelve month end active therapy ; pregnancy breast feeding ; psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule ; patient unable comply protocol ; active alcohol drug abuse ; malignancy within past three year basal cell skin cancer , carcinoma situ cervix ; contraindication therapy docetaxel ; history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 ( Tween 80 ) ; hypersensitivity BIBF 1120 and/or excipients trial drug ; hypersensitivity contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>